Corvus Pharmaceuticals, Inc. (CRVS)

Over the past six months, Corvus Pharmaceuticals' stock price has been impacted by several events. In November 2025, the company provided a business update and reported Q3 2025 financial results. January 2026 saw a significant surge in the company's shares after the announcement of positive Phase 1 trial data for soquelitinib in atopic dermatitis, followed by an upsized underwritten public offering. In February 2026, Corvus Pharmaceuticals presented at the Oppenheimer 36th Annual Healthcare Life Sciences Conference. March 2026 included a business update and the reporting of fourth quarter and full-year 2025 financial results. In April 2026, the company announced the appointment of Andrew C. Chan, M.D., Ph.D., to its Board of Directors and plans to host an investor and analyst meeting in May 2026 to highlight soquelitinib data. On May 7, 2026, Corvus Pharmaceuticals provided a business update and reported its first-quarter 2026 financial results, noting key clinical advances for soquelitinib and a cash runway into Q2 2028. While the stock's price has increased significantly over the last 12 months, it experienced a decrease in the past month.

As a clinical-stage biopharmaceutical company without commercialized products, Corvus Pharmaceuticals does not experience demand seasonality in the traditional sense. Its financial performance is primarily driven by its research and development activities and the progress of its clinical trials. Securing future funding is critical for its ongoing operations.

Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies targeting proteins crucial for immune cell function, with applications in cancer and immune diseases. The company is pioneering ITK inhibition as a new approach to immunotherapy. Its lead product candidate, soquelitinib, is in clinical trials for various conditions, and the company's pipeline includes ciforadenant and mupadolimab.

Corvus Pharmaceuticals is headquartered in South San Francisco, California, and primarily develops its product candidates in the United States. The company has a licensing agreement with Angel Pharmaceuticals for development and commercialization in Greater China. Clinical trials are conducted in multiple regions, including the United States and Europe, in collaboration with academic centers and oncology consortia.

Corvus Pharmaceuticals' brand reputation is closely linked to its clinical trial progress and scientific innovation. Positive Phase 1 clinical trial results for soquelitinib in atopic dermatitis and a successful public offering have bolstered its reputation in the past year. Continued progress in its clinical pipeline further solidifies its standing. However, the company's reputation also faces risks due to the inherent volatility of its share price and its reliance on external funding for its clinical-stage operations.

Corvus Pharmaceuticals, Inc. has 136 institutional owners and shareholders, holding a total of 47,818,010 shares. Major institutional shareholders include Orbimed Advisors Llc, BlackRock, Inc., Vanguard Group Inc, Morgan Stanley, Adams Street Partners Llc, Point72 Asset Management, L.P., State Street Corp, MPM Oncology Impact Management LP, Vivo Capital, LLC, and Geode Capital Management, Llc. As of January 2026, retail investors held the largest share of the company with 39% ownership, while institutions also owned 39%. Hedge funds held 8.6% of the shares. Insiders own 22.33% of the company's stock.